Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sugemalimab: First Approval.

Drugs - 1 Apr 2022

Dhillon Sohita, Duggan Sean

Abstract excerpt

Sugemalimab (Cejemly® in China) is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb) that is being developed by CStone Pharmaceuticals for the treatment of advanced solid tumours and lymphoma. In December 2021, sugemalimab was approved in China for the first-line treatment of epidermal growth factor receptor (EGFR) gene mutation and anaplastic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Carboplatin
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Mutation

Share to Receptor Protein-Tyrosine Kinases

Source

Identifiers

PMID: 35298827
DOI: 10.1007/s40265-022-01693-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sugemalimab: First Approval.PMID 35298827Read ↗

Efficacy and Safety of Ensartinib in the Treatment of Non-Small Cell Lung Cancer: A Systematic Review of Clinical TrialsSemantic proximity Read ↗

Befotertinib: First Approval.Semantic proximity Read ↗

Furmonertinib: First Approval.Semantic proximity Read ↗

Sevabertinib: First Approval.Semantic proximity Read ↗

Fulzerasib: First Approval.Semantic proximity Read ↗

Nivolumab plus ipilimumab for elderly Chinese patients with advanced non-small cell lung cancerSemantic proximity Read ↗

A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040).Semantic proximity Read ↗

Sunvozertinib: First Approval.Semantic proximity Read ↗

Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial.Semantic proximity Read ↗

[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version)].Semantic proximity Read ↗

A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Mobocertinib: Mechanism of action, clinical, and translational science.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.